Lipocine Inc. (NASDAQ: LPCN)
$6.50
-0.4100 ( -5.93% ) 27.8K
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Market Data
Open
$6.50
Previous close
$6.91
Volume
27.8K
Market cap
$34.71M
Day range
$6.33 - $7.10
52 week range
$2.31 - $11.79
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Nov 08, 2023 |
10-q | Quarterly Reports | 66 | Nov 08, 2023 |
8-k | 8K-related | 15 | Nov 01, 2023 |
8-k | 8K-related | 14 | Oct 26, 2023 |
8-k | 8K-related | 42 | Oct 24, 2023 |
8-k | 8K-related | 13 | Oct 06, 2023 |
8-k | 8K-related | 15 | Sep 19, 2023 |
8-k | 8K-related | 15 | Aug 10, 2023 |
10-q | Quarterly Reports | 65 | Aug 10, 2023 |
8-k | 8K-related | 37 | Jul 27, 2023 |